OEA (Oleoylethanolamide).

OEA and PEA are both N-acylethanolamides broken down by FAAH and NAAA and both act at PPAR-alpha. Given together they compete for the same degrading enzymes, so each persists longer than it would alone.

Cannabidiol competes for the fatty acid binding proteins that carry acylethanolamides to FAAH and slows their breakdown. Both actions leave OEA and its relatives circulating at higher levels.

Oleamide is a primary fatty acid amide cleared by the same FAAH enzyme that degrades OEA. Present together they compete for that single clearance route and both last longer.

OEA acts largely through the nuclear receptor PPAR-alpha, and long-chain omega-3 fatty acids are natural ligands at the same receptor. Two inputs onto one transcription factor governing normal fat handling.

OEA is lipophilic and absorbs unevenly from a dry powder. A medium-chain triglyceride carrier or a fat-containing meal improves micellar uptake.

Oleoylethanolamide is made in the body from N-acyl phosphatidylethanolamine, which forms when an oleoyl group is transferred onto the ethanolamine head group of a membrane phospholipid. Lecithin supplies that phospholipid pool. Supplying substrate is not the same as raising the finished molecule, and no trial has measured that step. The relationship is biochemical rather than clinical.

Phosphatidylcholine sits in the same membrane phospholipid pool that feeds N-acyl phosphatidylethanolamine synthesis, and the two head groups interconvert through established routes. This makes it a background substrate rather than a direct partner. No combination measurement exists. Read it as mechanistic context for a formula that carries both.

The oleoyl chain in oleoylethanolamide is oleic acid, the dominant fatty acid in olive oil, and dietary oleic acid is the acyl source the intestine uses when it makes this molecule after a fat-containing meal. Olive oil also serves as the carrier lipid in many softgel fills. The link is compositional and settled. It does not imply that olive oil intake raises circulating oleoylethanolamide by any particular amount.

Fatty acid amide hydrolase breaks down the whole N-acylethanolamide family, so docosahexaenoylethanolamide formed from DHA and oleoylethanolamide compete for the same enzyme. Higher DHA intake shifts the mix of acylethanolamides in tissue. Whether that changes the effect of supplemented oleoylethanolamide in people has not been measured. It is a real biochemical interaction stated at its true strength.

EPA gives rise to eicosapentaenoylethanolamide through the same route, and the same hydrolase clears it. Co-supplying long-chain omega-3 therefore changes which acylethanolamides are present rather than simply adding to the total. No human combination work exists. The competition is at the enzyme, not at the receptor.

Boron citrate and oleoylethanolamide were given together in a small clinical study of hospitalised adults with an acute infection, which is the only report placing the two in one protocol. A single pilot-scale study does not establish that the pairing does anything the components do not do alone. The mechanism connecting them is not defined. It is recorded because the combination was actually tested.

Oleoylethanolamide supplementation was reported to enrich Akkermansia muciniphila and to alter intestinal barrier measures, which places it in the same space as live culture products aimed at barrier support. That is an overlap in target, not a demonstrated combination. Whether co-dosing adds anything is untested. The change described is a microbial and barrier marker rather than a clinical outcome.

Fermentable fructans are the conventional way to shift Akkermansia and related mucosal organisms, and oleoylethanolamide has been reported to move the same organism through a different route. Two levers on one target is a reasonable formulation idea and an untested one. There is no combination data. The row records the overlap, nothing more.

Oleoylethanolamide carries a monounsaturated acyl chain that can oxidise in a lipid fill, and tocopherol is the usual antioxidant added to hold that in check. The role is stability, not activity. It appears on the ingredient line for that reason. No pharmacological interaction is implied.

Oleoylethanolamide has been pooled for effects on cardiometabolic markers and berberine is studied for support of normal glucose handling through unrelated chemistry. Placing both in a formula stacks two pushes on the same marker panel. No combination measurement exists, and markers are not outcomes. The row is a formulation flag.

Trials of oleoylethanolamide have reported movement in oxidative stress markers, an area where alpha-lipoic acid is a long-standing component. The two act through different chemistry and have not been given together. Any expectation of additivity is an inference. Oxidative markers are laboratory measures, not felt effects.